Your shopping cart is currently empty

AZA1 (Rac1/Cdc42-IN-1) is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induced apoptosis of prostate cancer cells and inhibited cell proliferation, migration and invasion.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $83 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $328 | In Stock | In Stock | |
| 25 mg | $548 | In Stock | In Stock | |
| 50 mg | $782 | In Stock | In Stock | |
| 100 mg | $1,060 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $223 | In Stock | In Stock |
| Description | AZA1 (Rac1/Cdc42-IN-1) is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induced apoptosis of prostate cancer cells and inhibited cell proliferation, migration and invasion. |
| In vitro | AZA1 (Rac1/Cdc42-IN-1) (2-10 μM; 72 hours) impedes the proliferation of human 22Rv1 prostate cancer cells, diminishes phosphorylation of PAK1, AKT, and BAD in EGF-stimulated 22Rv1 cells (2-10 μM; 24 hours), and obstructs Rac1 and Cdc42-dependent cell cycle progression (10 μM; 24 hours). AZA1 also inhibits Rac1 and Cdc42-dependent migration of 22Rv1, DU 145, and PC-3 prostate cancer cells, impacting cell motility and actin reorganization through PAK1/2 phosphorylation suppression. |
| In vivo | AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) effectively suppresses human 22Rv1 xenograft growth in 5-week-old athymic nu/nu (nude) mice and improves survival, with a significant impact on tumor growth suppression.[1] |
| Synonyms | Rac1/Cdc42-IN-1 |
| Molecular Weight | 368.43 |
| Formula | C22H20N6 |
| Cas No. | 1071098-42-4 |
| Smiles | Cc1cc2cc(Nc3ccnc(Nc4ccc5[nH]c(C)cc5c4)n3)ccc2[nH]1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (162.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.43 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.